Metabolic Complications of Acromegaly.
Authors: Mercado M, Ramírez-Rentería C Abstract Diabetes is recognized as one of the most common acromegaly co-morbidities with a prevalence ranging 20-53%, while over one-third of these patients have an altered lipid profile. In fact, as in the non-acromegalic population, carbohydrate and lipid metabolism abnormalities are closely linked. Long term exposure to an excess of growth hormone (GH) and Insulin-like growth factor-1 concentrations results in insulin resistance and an increased hepatic glucose production. The lipolytic effect of GH results in the mobilization of free fatty acids that further ...
Source: Frontiers of Hormone Research - June 13, 2018 Category: Endocrinology Tags: Front Horm Res Source Type: research

Screening of acromegaly in adults with obstructive sleep apnea: is it worthwhile?
(Source: Endocrine)
Source: Endocrine - June 12, 2018 Category: Endocrinology Source Type: research

Relation of RANKL and OPG Levels with Bone Resorption in Patients with Acromegaly and Prolactinoma
The objective of this study was to investigate the effect of hyperprolactinemia and high levels of insulin-like growth factor-I (IGF-I) on bone resorption and their relation with receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin (OPG) in patients with prolactinoma and acromegaly. Thirty-one patients with acromegaly, 28 patients with prolactinoma, and 33 healthy individuals were included in the study. Serum concentrations of RANKL, OPG, bone alkaline phosphatase (bone ALP), osteocalcin (OC), C-terminal telopeptide of type 1 collagen (CTX), procollagen type 1 N-terminal propeptide (P1NP)...
Source: Hormone and Metabolic Research - June 12, 2018 Category: Endocrinology Authors: Ozer, Firuzan Firat Dagdelen, Selcuk Erbas, Tomris Tags: Endocrine Care Source Type: research

The Role of Different Molecular Markers in Papillary Thyroid Cancer Patients with Acromegaly
Exp Clin Endocrinol Diabetes DOI: 10.1055/a-0629-9223 Purpose Prevalence of papillary thyroid cancer (PTC) is increased in patients with acromegaly. We aimed to determine the protein expression of BRAF, RAS, RET, insulin like growth factor 1(IGF1), Galectine 3, CD56 in patients with PTC related acromegaly and to compare the extensity of these expressions with normal PTC patients and benign thyroid nodules. Methods We studied 313 patients with acromegaly followed in Cerrahpasa Medical Faculty, Endocrinology and Metabolism Clinic between 1998 and 2015. On the basis of availability of pathological specimen of thyroid tissues,...
Source: Experimental and Clinical Endocrinology and Diabetes - June 11, 2018 Category: Endocrinology Authors: Keskin, Fatma Ela Ozkaya, Hande Mefkure Ferahman, Sina Haliloglu, Ozlem Karatas, Adem Aksoy, Figen Kadioglu, Pinar Tags: Article Source Type: research

Case Report: Persistent Acromegaly – Effective Therapy with Lanreotide and Weekly Pegvisomant Injections
Conclusions Excessive growth hormone secretion persisting after pituitary surgery and irradiation can be controlled in a convenient way for the patient with acromegaly by combining monthly lanreotide and weekly pegvisomant injections, if monotherapy with a somatostatin analog fails. [...] © Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents  |  Abstract  |  open access Full text (Source: Experimental and Clinical Endocrinology and Diabetes Reports)
Source: Experimental and Clinical Endocrinology and Diabetes Reports - June 11, 2018 Category: Endocrinology Authors: Sch ürmeyer, Thomas H. Galling, Britta Tags: Case Report Source Type: research

Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study.
Authors: Shen M, Wang M, He W, He M, Qiao N, Ma Z, Ye Z, Zhang Q, Zhang Y, Yang Y, Cai Y, ABuDuoReYiMu Y, Lu Y, Lu B, Shou X, Wang Y, Ye H, Li Y, Li S, Zhao Y, Cao X, Zhang Z Abstract Purpose: To evaluate the change in glucose tolerance in treatment-naïve patients with acromegaly after administration of SSA and to identify predictive factors of glucose impairment during SSA therapy. Methods: Oral glucose tolerance testing (OGTT) was performed on 64 newly diagnosed and treatment-naïve patients with acromegaly both at pretreatment and 3 months after initiation of treatment with long-acting SSA. Insulin ...
Source: International Journal of Endocrinology - June 3, 2018 Category: Endocrinology Tags: Int J Endocrinol Source Type: research

Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?
ConclusionElevated UII levels are associated with severity of cardiovascular risk factors including cIMT and EFT in acromegalic subjects. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - May 26, 2018 Category: Endocrinology Source Type: research

A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly.
CONCLUSIONS: Baseline median IGF-I was 447 and 649 ng/mL in the once- and twice-weekly groups, respectivey. Compared to baseline, at week 14 twice-weekly ATL1103 resulted in a median fall in IGF-I of 27.8% (p=0.0002). Between cohort comparison at week 14 demonstrated the median fall in IGF-I to be 25.8% (p=0.0012) greater with twice-weekly dosing. In the twice-weekly cohort, IGF-I was still declining at week 14, and at week 21 remained lower than at baseline by a median of 18.7% (p=0.0005). Compared to baseline, by week 14 IGFBP3 and ALS had declined by a median of 8.9% (p=0.027) and 16.7% (p=0.017) with twice-weekly ATL11...
Source: European Journal of Endocrinology - May 22, 2018 Category: Endocrinology Authors: Trainer PJ, Newell-Price J, Ayuk J, Aylwin S, Rees DA, Drake W, Chanson P, Brue T, Webb SM, Montañana CF, Aller J, McCormack AI, Torpy DJ, Tachas G, Atley L, Ryder D, Bidlingmaier M Tags: Eur J Endocrinol Source Type: research

Stereotactic radiation therapy for the treatment of functional pituitary adenomas associated with feline acromegaly
Journal of Veterinary Internal Medicine, EarlyView. (Source: Journal of Veterinary Internal Medicine)
Source: Journal of Veterinary Internal Medicine - May 21, 2018 Category: Veterinary Research Authors: Tiffany L.Wormhoudt , Mary ‐KearaBoss , KatharineLunn , LynnGriffin , DelLeary , KristyDowers , SangeetaRao , Susan M.LaRue Source Type: research

A giant on the ground: another large-bodied Atractus (Serpentes: Dipsadinae) from Ecuadorian Andes, with comments on the dietary specializations of the goo-eaters snakes.
We described herein a new species in the highly diversified and species-rich genus Atractus on the basis of four specimens from the southeastern slopes of the Ecuadorian Andes. The new species is morphologically similar and apparently closely related to two other allopatric giant congeners (A. gigas and A. touzeti), from which it can be distinguished by their distinct dorsal and ventral coloration, the number of supralabial and infralabial scales, the number of maxillary teeth, and relative width of the head. In addition, we discuss on the ontogenetic trajectories hypotheses and dietary specializations related to evolution...
Source: An Acad Bras Cienc - May 17, 2018 Category: Science Authors: Passos P, Scanferla A, Melo-Sampaio PR, Brito J, Almendariz A Tags: An Acad Bras Cienc Source Type: research

Mortality in Acromegaly decreased in the last decade: A Systematic Review and Meta-Analysis.
CONCLUSION: Mortality in acromegaly is normalized with biochemical control and decreased in the last decade with the more frequent use of SAs as adjuvant therapy. Increased life expectancy has been associated with more deaths due to cancer. PMID: 29764907 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - May 15, 2018 Category: Endocrinology Authors: Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS Tags: Eur J Endocrinol Source Type: research

An orphan G-protein-coupled receptor causes human gigantism and/or acromegaly: Molecular biology and clinical correlations
Publication date: April 2018 Source:Best Practice & Research Clinical Endocrinology & Metabolism, Volume 32, Issue 2 Author(s): Giampaolo Trivellin, Laura C. Hernández-Ramírez, Jeremy Swan, Constantine A. Stratakis X-linked acrogigantism (X-LAG) is a recently described form of familial or sporadic pituitary gigantism characterized by very early onset GH and IGF-1 excess, accelerated growth velocity, gigantism and/or acromegaloid features. Germline or somatic microduplications of the Xq26.3 chromosomal region, invariably involving the GPR101 gene, constitute the genetic defect leading to ...
Source: Best Practice and Research Clinical Endocrinology and Metabolism - May 14, 2018 Category: Endocrinology Source Type: research

Acromegaly is associated with high fibroblast growth factor-21 levels
ConclusionFGF-21 levels were increased significantly in acromegaly group. Increased FGF-21 levels were significantly and independently associated with the state of acromegaly. Acromegaly may also be a FGF-21 resistance state independent from insulin resistance, glucose intolerance, obesity, hypertension and dyslipidemia. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - May 12, 2018 Category: Endocrinology Source Type: research

Characteristics of the upper respiratory tract in patients with acromegaly and correlations with obstructive sleep apnoea/hypopnea syndrome
To explore the radiological characteristics of the upper respiratory tract and their correlations with obstructive sleep apnoea/hypopnea syndrome (OSAHS) in patients with acromegaly. (Source: Sleep Medicine)
Source: Sleep Medicine - May 9, 2018 Category: Sleep Medicine Authors: Xiaopeng Guo, Lu Gao, Ya ’nan Zhao, Man Wang, Bo Jiang, Qiang Wang, Zihao Wang, Xiaohai Liu, Ming Feng, Renzhi Wang, Zhuhua Zhang, Bing Xing Source Type: research

IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas
ConclusionIGF-1 levels may increase to clinically significant levels during cabergoline treatment for PRL-adenoma. We suggest IGF-1 monitoring in all patients treated with dopamine agonists and not only in those presenting symptoms of acromegaly. (Source: Pituitary)
Source: Pituitary - May 4, 2018 Category: Endocrinology Source Type: research

Pituitary Diseases and Bone.
Authors: Mazziotti G, Frara S, Giustina A Abstract Neuroendocrinology of bone is a new area of research based on the evidence that pituitary hormones may directly modulate bone remodeling and metabolism. Skeletal fragility associated with high risk of fractures is a common complication of several pituitary diseases such as hypopituitarism, Cushing disease, acromegaly and hyperprolactinemia. As in other forms of secondary osteoporosis, pituitary diseases generally affect bone quality more than bone quantity and fractures may occur even in the presence of normal or low-normal bone mineral density as measured by dual-...
Source: Endocrine Reviews - April 25, 2018 Category: Endocrinology Tags: Endocr Rev Source Type: research

Higher Income and Integration into the Workforce Are the Main Factors Associated with Quality of Life in Acromegalic Patients in Northeastern Brazil.
Authors: GuimarãesSá AM, Ferreira PAM, Souza MT, Nascimento GC, da Silva Pereira Damianse S, de Carvalho Rocha VC, Dos Santos Faria M, de Souza Paiva Ferreira A Abstract Objective: To identify the factors associated with quality of life in patients with acromegaly with follow-up at the referral service in neuroendocrinology of the state of Maranhão, northeast Brazil. Methods: The Acromegaly Quality of Life Questionnaire (Acro-QoL) was used. Factors independently associated with quality of life were identified using multivariate linear regression, with p values 
Source: International Journal of Endocrinology - April 24, 2018 Category: Endocrinology Tags: Int J Endocrinol Source Type: research

Cystic tumors of the pituitary infundibulum: seminal autopsy specimens (1899 to 1904) that allowed clinical-pathological craniopharyngioma characterization
AbstractA heterogeneous group of epithelial cystic tumors developed at the infundibulum and the third ventricle disconcerted pathologists at the dawn of the twentieth century. Very little was known at that time about the physiological role played by the pituitary gland, and there was almost complete ignorance regarding the function of the hypothalamus. Acromegaly, or enlargement of acral body parts, described in 1886 by Pierre Marie, was the only disease linked to primary hypertrophies of the pituitary gland, known as “pituitary strumas”. A growing number of young patients manifesting an unexplained combination...
Source: Pituitary - April 21, 2018 Category: Endocrinology Source Type: research

Outcome of pregnancies in a large cohort of women with acromegaly
Clinical Endocrinology, EarlyView. (Source: Clinical Endocrinology)
Source: Clinical Endocrinology - April 18, 2018 Category: Endocrinology Authors: R.S. Jallad , I. Shimon , M. Fraenkel , V. Medvedovsky , A. Akirov , F.H. Duarte , M.D. Bronstein Source Type: research

An orphan G protein-coupled receptor causes human gigantism and/or acromegaly: Molecular biology and clinical correlations
Publication date: Available online 17 March 2018 Source:Best Practice & Research Clinical Endocrinology & Metabolism Author(s): Giampaolo Trivellin, Laura C. Hernández-Ramírez, Jeremy Swan, Constantine A. Stratakis X-linked acrogigantism (X-LAG) is a recently described form of familial or sporadic pituitary gigantism characterized by very early onset GH and IGF-1 excess, accelerated growth velocity, gigantism and/or acromegaloid features. Germline or somatic microduplications of the Xq26.3 chromosomal region, invariably involving the GPR101 gene, constitute the genetic defect leading to ...
Source: Best Practice and Research Clinical Endocrinology and Metabolism - April 13, 2018 Category: Endocrinology Source Type: research

Cognitive-behavioral therapy improves the quality of life of patients with acromegaly
ConclusionThe technique presented herein effectively improved the quality of life of patients with acromegaly with different levels of disease activity, type, and treatment time. (Source: Pituitary)
Source: Pituitary - April 11, 2018 Category: Endocrinology Source Type: research

Impact of Glucose Metabolism Disorders on IGF-1 Levels in Patients with Acromegaly
In this study, we aimed to evaluate the presence of glucose metabolism abnormalities and their impact on IGF-1 levels in patients with acromegaly. Ninety-three patients with acromegaly (n=93; 52 males/41 females) were included in this study. Patients were separated into three groups such as; normal glucose tolerance (n=23, 25%), prediabetes (n=38, 41%), and diabetes mellitus (n=32, 34%). Insulin resistance was calculated with homeostasis model assessment (HOMA). HOMA-IR> 2.5 or ≤2.5 were defined as insulin resistant or noninsulin resistant groups, respectively. Groups were compared in terms of factors that may...
Source: Hormone and Metabolic Research - April 11, 2018 Category: Endocrinology Authors: Dogansen, Sema Ciftci Yalin, Gulsah Yenidunya Tanrikulu, Seher Yarman, Sema Tags: Endocrine Care Source Type: research

IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apnea
ConclusionsOur data demonstrate a low prevalence of acromegaly in patients with OSAS. Until data from population-based studies is available we suggest restricting screening for acromegaly in OSAS to those patients who have additional clinical features of acromegaly. (Source: Endocrine)
Source: Endocrine - April 10, 2018 Category: Endocrinology Source Type: research

Predictors of surgical outcome and early criteria of remission in acromegaly
AbstractBackgroundTranssphenoidal surgery (TSS) is the cornerstone of acromegaly treatment, however there are no robust predictors of surgical outcome and remission can only be defined three months after surgery.PurposeTo analyze if biochemical, demographical, radiological, and immunohistochemical characteristics are predictors of surgical remission and investigate if immediate postoperative GH and IGF-I levels can help defining remission earlier.MethodsConsecutive acromegaly patients submitted to TSS between 2013-2016 were evaluated. Remission criteria was defined as normal IGF-I and GH
Source: Endocrine - April 6, 2018 Category: Endocrinology Source Type: research

Treatment escape reduces the effectiveness of cabergoline during long ‐term treatment of acromegaly in monotherapy or in association with first‐generation somatostatin receptor ligands
Clinical Endocrinology, EarlyView. (Source: Clinical Endocrinology)
Source: Clinical Endocrinology - April 6, 2018 Category: Endocrinology Authors: Leandro Kasuki , Marilia Duarte Dalmolin , Luiz Eduardo Wildemberg , M ônica R. Gadelha Source Type: research

Use of electronic health records to characterize a rare disease in the usa: treatment, comorbidities and follow-up trends among patients with a confirmed diagnosis of acromegaly
Endocrine Practice, Ahead of Print. (Source: Endocrine Practice)
Source: Endocrine Practice - April 6, 2018 Category: Endocrinology Authors: Julie M Silverstein Erin D Roe Kashif M Munir Janet L Fox Birol Emir Maria Kouznetsova Lois E Lamerato Donna King Source Type: research

GH, IGF-1, and Age Are Important Contributors to Thyroid Abnormalities in Patients with Acromegaly.
Conclusions: Both benign and malignant thyroid abnormalities are increased in the acromegalic population compared to those in the general population. Age at diagnosis is an independent risk factor for thyroid abnormalities, and GH burden may be a partial contributor. Early diagnosis, early treatment, and monitoring of postoperational endocrine levels are important for acromegalic patients. PMID: 29593792 [PubMed] (Source: International Journal of Endocrinology)
Source: International Journal of Endocrinology - March 31, 2018 Category: Endocrinology Tags: Int J Endocrinol Source Type: research

How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review
ConclusionsThe way GH and IGF-1 are measured and reported in acromegaly research varies considerably. A consensus on how to report study results would enable better comparisons between studies, thereby improving evidence based decision making to optimize treatment in acromegaly. (Source: Pituitary)
Source: Pituitary - March 31, 2018 Category: Endocrinology Source Type: research

Persistence of Diabetes and Hypertension after Multimodal Treatment of Acromegaly.
Conclusion: Our findings underscore the importance of an integral approach when managing these patients, focusing not only on the control of GH and IGF-1 levels but also on the timely diagnosis and the specific treatment of each co-morbidity. PMID: 29618021 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - March 30, 2018 Category: Endocrinology Authors: González B, Vargas G, Espinosa de Los Monteros AL, Mendoza V, Mercado M Tags: J Clin Endocrinol Metab Source Type: research

Expression of the long non-coding RNA H19 and MALAT-1 in growth hormone-secreting pituitary adenomas and its relationship to tumor behavior.
Abstract Aggressive growth hormone-secreting pituitary adenomas (GHPAs) represent an important clinical problem in patients with acromegaly. Surgical therapy, although often the mainstay of treatment for GHPAs, is less effective in aggressive GHPAs due to their invasive and destructive growth patterns, and their proclivity for infrasellar invasion. LncRNAs are important players in cancer development and emerging in various fundamental biological processes. In the present study, qRT-PCR was performed to examine the expression of lncRNA H19 and MALAT-1 in invasive and non-invasive GHPAs. Our results revealed that th...
Source: International Journal of Developmental Neuroscience - March 28, 2018 Category: Neuroscience Authors: Lu T, Yu C, Ni H, Liang W, Yan H, Jin W Tags: Int J Dev Neurosci Source Type: research

The kinetoplastid-infecting Bodo saltans virus (BsV), a window into the most abundant giant viruses in the sea
Giant viruses are ecologically important players in aquatic ecosystems that have challenged concepts of what constitutes a virus. Herein, we present the giant Bodo saltans virus (BsV), the first characterized representative of the most abundant group of giant viruses in ocean metagenomes, and the first isolate of a klosneuvirus, a subgroup of theMimiviridae proposed from metagenomic data. BsV infects an ecologically important microzooplankton, the kinetoplastidBodo saltans. Its 1.39 Mb genome encodes 1227 predicted ORFs, including a complex replication machinery. Yet, much of its translational apparatus has been lost, incl...
Source: eLife - March 27, 2018 Category: Biomedical Science Tags: Genomics and Evolutionary Biology Microbiology and Infectious Disease Source Type: research

Pasireotide - mechanism of action and clinical applications.
Abstract Pasireotide (SOM230) is a multi-receptor ligand somatostatin analogue (SSA) developed as the successor of the first-generation SSAs. Currently, pasireotide is recommended for the treatment of patients with Cushing's disease in whom surgery was unsuccessful, and patients with acromegaly who either remain uncontrolled after surgical therapy or in whom tumor resection is not possible. Phase II and III clinical trials have shown pasireotide efficacy in these diseases, with a similar rate of adverse events when compared with first-line SSA, although higher incidence of hyperglycemia has been observed. Pasireot...
Source: Current Drug Metabolism - March 27, 2018 Category: Drugs & Pharmacology Authors: Sawicka-Gutaj N, Owecki M, Ruchala M Tags: Curr Drug Metab Source Type: research

Endonasal endoscopic surgery in pituitary adenomas: Surgical results in a series of 86 consecutive patients.
CONCLUSIONS: In terms of surgical quality, our results are similar to those of published series, and demonstrate the efficacy and safety of the endoscopic endonasal approach as the surgical treatment of choice for pituitary adenomas. However, further studies with a higher sample size are necessary to obtain clinically significant results. PMID: 29580720 [PubMed - as supplied by publisher] (Source: Neurocirugia)
Source: Neurocirugia - March 23, 2018 Category: Neurosurgery Authors: López-García R, Abarca-Olivas J, Monjas-Cánovas I, Picó Alfonso AM, Moreno-López P, Gras-Albert JR Tags: Neurocirugia (Astur) Source Type: research

Cancer Incidence in Patients with Acromegaly: A cohort study and meta-analysis of the literature.
rgensen JOL Abstract Context: Acromegaly has been associated with increased risk of cancer morbidity and mortality, but research findings remain conflicting and population-based data are scarce. We therefore examined whether patients with acromegaly are at higher risk of cancer. Design: A nationwide cohort study (1978-2010) including 529 acromegaly cases was performed. Incident cancer diagnoses and mortality were compared to national rates estimating standardized incidence ratios (SIRs). A meta-analysis of cancer SIRs from 23 studies (including the present one) was performed. Results: The cohort study id...
Source: The Journal of Clinical Endocrinology and Metabolism - March 23, 2018 Category: Endocrinology Authors: Dal J, Leisner MZ, Hermansen K, Farkas DK, Bengtsen M, Kistorp C, Nielsen EH, Andersen M, Feldt-Rasmussen U, Dekkers OM, Sørensen HT, Jørgensen JOL Tags: J Clin Endocrinol Metab Source Type: research

Somatostatin Analogs and Glucose Metabolism in Acromegaly: A Meta-analysis of Prospective Interventional Studies.
Abstract Introduction: Somatostatin analogs (SSAs) effectivelycontrol growth hormone secretion in first and second line treatmentof acromegaly. Their effect onglucose metabolism is still debated. Aim: to address the following questions: 1) Do SSAs affect fasting plasma glucose (FPG), fasting plasma insulin (FPI), glycosylated hemoglobin (HbA1c), glucose load (2h-OGTT), HOMA-I, HOMA-β, triglycerides (TGD), weight (W) or body mass index (BMI)? 2) Do lanreotide (LAN) and octreotide LAR (OCT) affect metabolism differently? 3)Does their effect depend on disease control? Methods: We performed a meta-analy...
Source: The Journal of Clinical Endocrinology and Metabolism - March 23, 2018 Category: Endocrinology Authors: Cozzolino A, Feola T, Simonelli I, Puliani G, Pozza C, Giannetta E, Gianfrilli D, Pasqualetti P, Lenzi A, Isidori AM Tags: J Clin Endocrinol Metab Source Type: research

Three ‐dimensional speckle tracking echocardiography–derived left atrial deformation analysis in acromegaly (Results from the MAGYAR‐Path Study)
Echocardiography, EarlyView. (Source: Echocardiography)
Source: Echocardiography - March 22, 2018 Category: Cardiology Source Type: research

Biomarkers of GH action in children and adults.
This article will review biomarkers, surrogate endpoints and clinical endpoints related to GH treatment in children and adults as well as in acromegaly. PMID: 29601998 [PubMed - as supplied by publisher] (Source: Growth Hormone and IGF Research)
Source: Growth Hormone and IGF Research - March 20, 2018 Category: Endocrinology Authors: Schilbach K, Olsson DS, Boguszewski MCS, Bidlingmaier M, Johannsson G, Jørgensen JL Tags: Growth Horm IGF Res Source Type: research

An orphan G protein-coupled receptor causes human gigantism and/or acromegaly: molecular biology and clinical correlations
X-linked acrogigantism (X-LAG) is a recently described form of familial or sporadic pituitary gigantism characterized by very early onset GH and IGF-1 excess, accelerated growth velocity, gigantism and/or acromegaloid features. Germline or somatic microduplications of the Xq26.3 chromosomal region, invariably involving the GPR101 gene, constitute the genetic defect leading to X-LAG. GPR101 encodes a class A G protein-coupled receptor that activates the 3',5'-cyclic adenosine monophosphate signaling pathway. (Source: Best Practice and Research. Clinical Endocrinology and Metabolism)
Source: Best Practice and Research. Clinical Endocrinology and Metabolism - March 17, 2018 Category: Endocrinology Authors: Giampaolo Trivellin, Laura C. Hern ández-Ramírez, Jeremy Swan, Constantine A. Stratakis Source Type: research

An orphan G-protein-coupled receptor causes human gigantism and/or acromegaly: Molecular biology and clinical correlations
X-linked acrogigantism (X-LAG) is a recently described form of familial or sporadic pituitary gigantism characterized by very early onset GH and IGF-1 excess, accelerated growth velocity, gigantism  and/or acromegaloid features. Germline or somatic microduplications of the Xq26.3 chromosomal region, invariably involving the GPR101 gene, constitute the genetic defect leading to X-LAG. GPR101 encodes a class A G protein-coupled receptor that activates the 3′,5′-cyclic adenosine monophosphat e signaling pathway. (Source: Best Practice and Research. Clinical Endocrinology and Metabolism)
Source: Best Practice and Research. Clinical Endocrinology and Metabolism - March 17, 2018 Category: Endocrinology Authors: Giampaolo Trivellin, Laura C. Hern ández-Ramírez, Jeremy Swan, Constantine A. Stratakis Tags: 5 Source Type: research

Pre- and Postoperative Body Composition and Metabolic Characteristics in Patients with Acromegaly: A Prospective Study.
Conclusions: Body composition and metabolism in acromegaly patients changed after surgery, and gender and age influenced these changes. PMID: 29531529 [PubMed] (Source: International Journal of Endocrinology)
Source: International Journal of Endocrinology - March 14, 2018 Category: Endocrinology Tags: Int J Endocrinol Source Type: research

Does IGF-1 play a role in the etiopathogenesis of non-functioning adrenocortical adenoma?
This study included 50 female patients (mean age 54  years) with NFAs, 55 patients (mean age 48 years; 20 male, 35 female) with acromegaly and 38 female control subjects (mean age 58 years). Body mass index (BMI) and waist circumference (WC) of the subjects were recorded and blood samples for IGF-1 were taken. Insulin resistance was calculated usi ng the homeostatic model assessment (HOMA) score. Since most of the acromegaly patients had been using medicine that could have effected insulin resistance, HOMA scores were calculated only in patients with NFAs and the controls. Computerized tomography or magnetic...
Source: Journal of Endocrinological Investigation - March 14, 2018 Category: Endocrinology Source Type: research

Treatment escape reduces the effectiveness of cabergoline during long ‐term treatment of acromegaly in monotherapy or in association with first‐generation somatostatin receptor ligands
Abstract BackgroundFew studies evaluated the use of cabergoline (CAB) for acromegaly treatment in monotherapy or in combination with first‐generation somatostatin receptor ligands (SRLs). AimEvaluate the efficacy, predictors of response and safety of CAB treatment in acromegaly both in monotherapy and in combination with SRLs. MethodsWe retrospectively collected demographic, biochemical, tumor and treatment data. Short‐term disease control was defined as random GH level
Source: Clinical Endocrinology - March 9, 2018 Category: Endocrinology Authors: Leandro Kasuki, Marilia Duarte Dalmolin, Luiz Eduardo Armondi Wildemberg, M ônica R. Gadelha Tags: 4 Original Article ‐ Americas Source Type: research

Pachydermoperiostosis in a patient with chronic hepatitis B virus infection referred as acromegaly: a case report
ConclusionsThe possible role of hepatitis B in hypertrophic osteoarthropathy, that is, secondary hypertrophic osteoarthropathy, needs to be explored; however, with digital clubbing in his father our patient is likely to have pachydermoperiostosis. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - March 8, 2018 Category: General Medicine Source Type: research

Oro-dental pathologies in acromegaly
ConclusionIn our large series of patients, four of five patients were affected by ODP at any time during the course of the disease. The results highlight the importance of early identification and treatment of oro-dental problems in patients with acromegaly as hallmarks of the disease. (Source: Endocrine)
Source: Endocrine - March 8, 2018 Category: Endocrinology Source Type: research

Value of early postoperative random growth hormone levels and nadir growth hormone levels after oral glucose tolerance testing in acromegaly.
Abstract OBJECTIVE: There is no ideal marker to identify residual tumor tissue after surgery in patients with acromegaly. The purpose was to elucidate if early postoperative hormone testing gives reliable information regarding complete resection of a GH-producing pituitary adenoma. DESIGN: Fourty-eight patients undergoing surgery for acromegaly from 04/2013-05/2014 were prospectively examined for random GH, IGF1, and GH levels after oral glucose tolerance testing (OGTT) in the early postoperative phase and on follow-up. Criterion for inclusion was a minimum follow-up of one year for each patient with respect ...
Source: Growth Hormone and IGF Research - March 8, 2018 Category: Endocrinology Authors: Rotermund R, Burkhardt T, Rohani Z, Jung R, Aberle J, Flitsch J Tags: Growth Horm IGF Res Source Type: research

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
Rosa Maria Paragliola, Roberto Salvatori (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - March 7, 2018 Category: Endocrinology Source Type: research

Radiotherapy in acromegaly: long-term brain parenchymal and vascular magnetic resonance changes
Conclusions RT seems to have created a cohort of patients with brain parenchymal changes whose clinical and cognitive impact is still unknown. These patients might require a prolonged MRI and MRA follow-up to promptly detect delayed RT-related complications and minimize their clinical consequences. (Source: Journal of Neuroradiology)
Source: Journal of Neuroradiology - March 2, 2018 Category: Radiology Source Type: research